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2.  ABBREVIATIONS 
AJCC American Joint Committee on Cancer 
ALT anterolateral thigh 
ASA American Society of Anesthesiologists 
CT computed tomography 
DFS disease-free survival 
DFSP dermatofibrosarcoma protuberans 
DSOS disease-specific overall survival 
EBRT external beam radiotherapy 
FDG 18F-fluorodeoxyglucose 
FLT 18F-fluorothymidine 
FNCLCC Fédération Nationale des Centres Lutte Contre le Cancer 
FQA  forequarter amputation 
GIST gastrointestinal stromal tumor 
HUCH Helsinki University Central Hospital 
ILP isolated limb perfusion 
LD latissimus dorsi 
LRFS local recurrence-free survival 
MDACC M.D. Anderson Cancer Center 
MFH malignant fibrous histiocytoma 
MFS metastasis-free survival 
MPNST malignant peripheral nerve sheath tumor 
MRI magnetic resonance imaging 
MSKCC Memorial Sloan Kettering Cancer Center 
MSTS Musculoskeletal Tumor Society 
NOS not otherwise specified 
OS overall survival 
OUH Oulu University Hospital 
PET  positron emission tomography 
PLP phantom limb pain 
RT  radiotherapy 
SSG Scandinavian Sarcoma Group 
SSS surgical staging system 
STS soft tissue sarcoma 
TAP thoracodorsal artery perforator 
TESS Toronto extremity salvage score 
TFL tensor fasciae latae 
TNF tumor necrosis factor 
UICC Unio Internationalis Contre Cancrum 
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3.  ABSTRACT 
 
Background 
Soft tissue sarcomas (STS) are rare tumors of soft tissue occurring most 
frequently in the extremities. Modern treatment of extremity STS is based on 
limb-sparing surgery combined with radiotherapy (RT), with other oncological 
treatment used less frequently. In order to prevent local recurrence, a healthy 
tissue margin of 2.5 cm around the resected tumor is required. This results in 
large defects of soft tissue and bone, necessitating the use of reconstructive 
surgery to achieve wound closure, especially in the distal parts of the 
extremities where soft tissues are scarce. When local or pedicled soft tissue 
flaps are unavailable or insufficient, reconstruction with free flaps is used. The 
free flaps are elevated at a distant site, and have their blood flow restored at the 
recipient site through microvascular anastomosis. When limb-sparing surgery is 
made impossible by tumor location or infiltration into vital structures, amputation 
is the only option. Proximal amputation such as forequarter amputation (FQA) 
causes considerable morbidity, but is nevertheless warranted for carefully 
selected patients for cure or palliation.  
Materials and Methods 
116 patients treated in 1985 - 2006 were included in the study. 73 patients 
treated with microvascular reconstructive surgery after resection of STS or 
related tumors of the lower extremity. 15 of these patients were treated for STS 
near the knee. 20 patients underwent microsurgical reconstructive surgery for 
STS or related tumors of the upper extremity. 25 patients who underwent 
forequarter amputation for STS or other malignant disease at Helsinki University 
Central Hospital (HUCH) or Oulu University Hospital (OUH) were also included. 
Patients were identified and their medical records retrospectively reviewed for 
data on demographics, tumor characteristics, treatment, and surgical, 
oncological and functional outcome. In all, 105 free flap procedures were 
performed for 103 patients. A total of 95 curatively treated STS patients were 
included in survival analysis.  
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Results 
The latissimus dorsi, used in 56% of cases, was the most frequently used free 
flap. Free flap success rate was 96%. There were 9% microvascular 
anastomosis complications and 15% wound complications. For curatively 
treated STS patients, local recurrence-free survival at 5 years was 73.1%, 
metastasis-free survival 58.3%, disease-free survival 50.1% and overall 
disease-specific survival 68.9%. Functional results were good, with 75% of 
patients regaining normal or near-normal function after lower extremity, and 
55% after upper extremity STS resection. Among 25 forequarter amputees, 
there was no perioperative mortality, and 5-year disease-free survival was 44% 
among curatively treated patients. In the palliatively treated group median time 
until disease death was 14 months.   
Conclusions 
Microvascular reconstruction after extremity soft tissue sarcoma resection is a 
safe and reliable method. Tension-free wound closure and cavity filling 
produces stable, well-healing wounds, allowing early oncological treatment. 
Oncological outcome after these procedures is comparable to that of other 
extremity sarcoma patients. Functional results are generally good. Forequarter 
amputation is a useful treatment option for soft tissue tumors of the shoulder 
girdle and proximal upper extremity and is associated with low operative 
morbidity. Acceptable oncological outcome is achieved for curatively treated 
FQA patients. In the palliatively treated patient increased quality of life can be 
achieved for considerable periods of time. When free flap coverage of extended 
forequarter amputation is required, the preferable flap is a fillet flap from the 
amputated extremity.  
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4.  INTRODUCTION 
 
Soft tissue sarcomas (STS) are rare tumors originating mainly from the 
embryonic mesoderm, the majority arising in the extremities (Pollock et al 1996; 
Nijhuis et al 1999). STS comprises less than 1% of all adult malignancies in 
Finland, with approximately 120 new cases diagnosed annually (Finnish Cancer 
Registry 2007).  
 
Due to high rates of local recurrence after simple tumor excision, amputation 
used to be the treatment of choice for STS of an extremity (Cantin et al 1968). 
Combination of surgery and radiotherapy (RT) proved to achieve equal 
oncologic results with considerably less invalidity (Rosenberg et al 1982; Yang 
et al 1998). Limb-sparing treatment protocols combining surgery, radiotherapy 
and chemotherapy have since become the gold standard in the treatment of 
extremity STS (Clark et al 2005, Tunn et al 2009).  
 
Oncologically safe resection of STS requires a healthy tissue margin of 1.5-2.5 
centimeters (Pisters et al 1996 (B), Sampo et al 2008). Extensive soft tissue and 
bone defects are frequently caused. To enable limb sparing and to achieve 
satisfactory functional and cosmetic results, reconstructive surgery is required in 
25-48% of patients (Popov et al 2000, Clarkson et al 2004, Popov et al 2004). 
Free flap reconstruction is necessary in 11-18% of patients (Lohman et al 2002, 
Kim et al 2004 (A), Papadopoulos et al 2006).  
 
Today, amputation for extremity STS is uncommon, but in 9-13% of patients it is 
still unavoidable (Pisters et al 1996 (B), Trovik et al 2001 (A), Trovik 2001 (B)). 
In patients with shoulder girdle or proximal upper extremity tumors, forequarter 
amputation (FQA) can provide an option when limb sparing proves impossible 
(Malawer et al 2001).  
 
The aim of this study was to review the use of free flaps in extremity STS 
surgery, and to evaluate factors affecting surgical and oncologic outcome. 
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5.  REVIEW OF THE LITERATURE 
 
5.1 Soft tissue sarcoma  
 
Soft tissue sarcomas (STS) are a heterogeneous group of tumors arising mainly 
from mesenchymal tissues. The most common anatomical sites are lower 
extremity (29-49%), upper extremity (12-21%), retroperitoneum (8-15%), head 
and neck (4-13%), abdomen (10-12%), pelvis (7-12%), and thorax (9-11%) 
(Pollock et al 1996, Nijhuis et al 1999, Weiss et al 2001, Lohman et al 2002, 
Zagars et al 2003 (A), Cormier et al 2004, Kim et al 2004 (A), Gutierrez et al 
2007 (A)). 
 
5.1.1 Incidence 
 
The incidence of soft tissue malignancies (ICD-10 codes C48-49) has been 
relatively constant, with approximately 2.0 new cases per 100 000 inhabitant-
years. This figure excludes tumors of the autonomous nervous system and 
peripheral nerves (ICD-10 codes C47). With these included, incidence in 2000-
2005 was 2.4/100 000, accounting for 0.9% of all adult cancers (Finnish Cancer 
Registry 2007).  
 
In the US one study found 3.8 cases per 100 000 inhabitant-years in 2003, 
(Gutierrez et al 2007 (A)). Another study states that STS accounts for 0.63% of 
new cancer diagnoses and 1.15% of all cancer deaths (Jemal et al 2004). Signs 
of a slight increase in the overall incidence of STS has been explained by both 
improved recognition and diagnostics (Ross et al 1993, Clark et al 2005), as 
well as by the increased number of AIDS-related Kaposi’s sarcomas (Zahm et al 
1997).  
 
5.1.2 Etiology 
 
The majority of STS are considered to be sporadic, i.e. no specific etiological 
factors can be identified (Lahat et al 2008 (B)). Several factors that may cause 
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STS have, however, been recognized. Radiation therapy increases the risk of 
both bone and soft tissue sarcoma (Brady et al 1992, Virtanen et al 2006). 
Chronic lymphedema may cause cutaneous lymphangiosarcoma (Grobmyer et 
al 2000). Angiosarcoma arising from chronic lymphedema after mastectomy and 
radiotherapy is known as Stewart-Treves syndrome (Stewart et al 1943). 
 
Environmental agents such as vinyl chloride, phenoxyacetic acid herbicides, 
and chlorophenols and their contaminants have been shown to increase the risk 
of sarcoma (Froehner et al 2001).  
 
Certain genetic conditions are associated with STS. These include 
neurofibromatosis I (caused by a mutation in 17q11), which causes multiple 
benign neurofibromas in the patient, 1-5% of which will present as aggressive 
malignant peripheral nerve sheath tumors (MPNST) (Evans et al 2002, Ferrari 
et al 2007). Mutations of the tumor suppressor gene p53 causes Li-Fraumeni 
syndrome, associated with a wide range of malignancies, including STS 
(Gonzales et al 2009). Familiar retinoblastoma, caused by mutations in the 
retinoblastoma gene RB I (Wong et al 1997), also increases risk of sarcoma. 
The phenotypical variant of familial adenomatous polyposis (FAP) known as 
Gardner’s syndrome is associated with increased risk of several neoplastic 
lesions, desmoid tumor among them (Lyster Knudsen et al 2001, Nieuwenhuis 
et al 2008). In Maffucci syndrome, benign enchondromas, hemangiomas and 
lymphangiomas may undergo transformation into their malignant sarcomatous 
counterparts (Albregts et al 1995).  
 
Also, some viral agents increasing the risk of STS have been identified. Human 
herpesvirus 8 (HHV 8) plays a role in the development of Kaposi’s sarcoma 
(Boshoff et al 2002, Sullivan et al 2008). Further, Epstein-Barr virus (EBV) 
infection has been found to cause leiomyosarcoma both in immunodeficient 
AIDS-patients (McClain et al 1995) and in organ-transplant recipients during 
therapeutic immunosuppression (Nur et al 2007). 
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5.1.3 Classification and histopathology 
 
Soft tissue sarcomas generally present as a painless mass, and histological 
confirmation of diagnosis is crucial before treatment. Core-needle biopsy (CNB) 
provides the correct diagnosis in 90% of cases, whereas fine-needle aspiration 
(FNA) may produce insufficient amounts of tissue (Barth et al 1992, Hoeber et al 
2001, Jones et al 2002). Infrequently, when tumor location is such that needle 
biopsy is not feasible, or when earlier biopsies have turned out inconclusive, 
incisional or open biopsy is warranted (Misra et al 2009). Care should be taken 
to place all incisions and biopsy tracts so that they can be easily excised en-bloc 
with sufficient healthy tissue margins with the biopsied tumor (Springfield et al 
1996, Leithner et al 2009). The rarity and heterogeneity of these tumors makes 
diagnosis difficult, and histopathologic examination should preferably be carried 
out by an experienced soft tissue tumor pathologist (Clark et al 2005, Palesty et 
al 2005, Bjerkehagen et al 2009). 
 
The World Health Organization Classification of Tumors now recognizes more 
than 50 distinct subtypes (Fletcher et al 2002). Undifferentiated pleomorphic 
sarcoma, previously known as malignant fibrous histiocytoma (MFH), is the 
most common type in adults, representing 28-39% of all STS.  Liposarcoma (14-
22%), synovial sarcoma (11-12%), leiomyosarcoma (6-12%), fibrosarcoma (8-
9%) and MPNST (6-7%), are also among the more common subtypes in several 
large series. (Zagars et al 2003 (A), Cormier et al 2004, Mankin et al 2005, 
Gadgeel et al 2009). Among 1261 patients with extremity STS, Weitz reported 
MFH (38%), liposarcoma (27%), synovial sarcoma (14%) fibrosarcoma (12%) 
and leiomyosarcoma (9%) to be the most common histologic findings (Weitz et 
al 2003). Gutierrez reported similar findings in 4205 surgically treated STS 
patients: 54% MFH, 34% liposarcoma, 10% fibrosarcoma, and 1% other or 
unspecified histology (Gutierrez et al 2007 (A)).  
 
The most prevalent subtype of STS is dependent on patient age, with MFH 
generally a disease of patients over 50 (Weiss et al 2001). Rhabdomyosarcoma 
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is by far the most common histologic finding in children, constituting more than 
50% of pediatric STS (Cormier et al 2004, Hayes-Jordan et al 2009). 
 
Histologic analysis supplemented by immunohistochemical analysis (Miettinen 
2003) and genetic profiling (Segal et al 2003, Mandahl et al 2004) has increased 
diagnostic accuracy as many subgroups of STS have been shown to exhibit 
specific chromosomal changes (Brennan 2005). 
 
5.1.4 Grading  
 
In order to anticipate patient prognosis, tumors are graded for histological 
aggressiveness. The first grading system for STS was introduced by Broders in 
1939, as a continuation on his work on squamous cell carcinoma (Broders 1920, 
Broders et al 1939). This 4-tiered system was based on mitotic activity, number 
of giant cells, and percentage of fibrous stroma in fibrosarcomas. Grades 1-2 
(G1-G2) were regarded as low grade, and 3-4 (G3-G4) as high grade tumors. A 
4-tiered system largely based on Broders’ classification is used by the 
Scandinavian Sarcoma Group (SSG), and is also used in Finland (Angervall et 
al 1993).  Also the 6th edition of the American Joint Committee on 
Cancer/International Union Against Cancer (AJCC/UICC) staging system uses a 
4-tiered system based on cellular differentiation (Greene et al 2002).  
 
Other grading systems were developed in the 80s; the 3-tiered system of the 
French Federation of Cancer Centers (FNCLCC) is based on cellular 
differentiation, mitotic rate, and tumor necrosis (Trojani et al 1984), whereas the 
3-tiered National Cancer Institute (NCI) system on histologic diagnosis, 
cellularity, cellular pleomorphism, and mitotic rate (Costa et al 1984). Both 3-
tiered systems use grade 1 (G1) for low grade, and grades 2-3 (G2-3) for high 
grade tumors. The most common system in use, and also the most 
reproducible, is the FNCLCC system (Guillou et al 1997, Golouh et al 2001). For 
clinical use, division into high or low grade is frequently the most practical, and a 
2-tiered system has been proposed (Deyrup et al 2006, Kotilingam et al 2006). 
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5.1.5 Staging 
 
Histological grade alone is not the only determinant of outcome. Staging 
systems use a variety of other factors to predict prognosis.  
 
The Musculoskeletal Tumor Society (MSTS) staging system, also known as the 
Surgical Staging System (SSS), is based on 3 variables (Enneking et al 1980, 
Wolf et al 1996). The first is malignancy grade, determined histologically by 
cytologic atypia and mitotic activity, defining tumors as either low-grade (G1) or 
high-grade (G2). Secondly, a difference is made between intracompartmental 
(T1) and extracompartmental (T2). Intracompartmental tumors are confined to a 
specific anatomical compartment, whereas extracompartmental tumors infiltrate 
the borders of, or extend beyond these compartments. Thirdly, the last division 
is based on the absence (M0) or presence (M1) of metastasis. The final 3-tiered 
staging is based on these factors (Table 1). 
 
TABLE 1. Surgical Staging System (SSS) of soft tissue sarcoma 
 
Stage Description Grade  Site Metastasis 
IA Low grade, intracompartmental G1 T1 M0 
IB Low grade, extracompartmental G1 T2 M0 
IIA High grade, intracompartmental G2 T1 M0 
IIB High grade, extracompartmental G2 T2 M0 
III Any grade, metastatic G1-2 T1-2 M1 
From Wolf et al 1996 
 
 
Another staging system, incorporating tumor size, site, and histologic grade as 
three prognostic factors, was developed at Memorial Sloan Kettering Cancer 
Center (MSKCC). Each of these factors is divided into two subcategories, 
favorable and unfavorable prognostic signs. The number of unfavorable signs 
then determines STS stages 0-III. Metastatic disease is always stage IV (Tables 
2 - 3) (Hajdu 1979, Hajdu et al 1988).  
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TABLE 2. Prognostic signs of the MSKCC staging system 
 
 Favorable prognostic signs Unfavorable prognostic signs 
Size (5cm/>5cm) Small Large 
Site (relative to deep fascia) Superficial Deep 
Histologic grade Low High 
From Hajdu et al 1988 
 
TABLE 3. MSKCC staging system 
 
Prognostic signs Stage of sarcoma 
Three favorable signs 0 
One unfavorable signs and 2 favorable signs I 
Two unfavorable signs and 1 favorable sign II 
Three unfavorable signs III 
Evidence of metastasis IV 
From Hajdu et al 1988 
 
The current 6th edition of the AJCC/UICC system is the most commonly used 
staging system (Kotilingam et al 2006). It incorporates tumor grade and size, as 
well as presence or absence of nodal (N0-N1) and distant metastases (M0-M1) 
(Table 4, Table 5) (Greene et al 2002). 
 
Wunder et al compared the above staging systems, and found the 5th edition of 
the AJCC/UICC system to be as accurate as the MSKCC system in predicting 
systemic disease relapse in patients with localized extremity STS, whereas the 
SSS was inferior to these (Wunder et al 2000).  
 
Accurate prediction of prognosis for STS patients has proven difficult. Even the 
latest staging systems have been criticized for not incorporating enough factors, 
among other things (Lahat et al 2008 (A)). An attempt towards better prediction 
of outcome has been made in the form of nomograms, notably one developed at 
MSKCC (Kattan et al 2002). It takes into account tumor size, depth and 
histology as well as anatomical site and patient age, and a 2005 variation of it 
also incorporates 3-tiered tumor grade according to FNCLCC grading (Mariani 
et al 2005).  
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TABLE 4. AJCC TNM classification 
 
Primary tumor (T) 
 TX Primary tumor cannot be assessed 
 T0 No evidence of primary tumor 
 T1 Tumor  5cm  
  T1a  Superficial tumor 
  T1b  Deep tumor 
 T2 Tumor > 5cm 
  T2a  Superficial tumor 
  T2b  Deep tumor 
Regional lymph nodes (N) 
 NX Regional lymph nodes cannot be assessed 
 N0 No regional lymph node metastasis 
 N1 Regional lymph node metastasis 
Distant metastasis (M) 
 MX Metastasis cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis 
Histologic grade (G) 
 GX Grade cannot be assessed 
 G1 Well differentiated 
 G2 Moderately differentiated 
 G3 Poorly differentiated 
 G4 Poorly differentiated or undifferentiated 
From Greene et al 2002 
 
TABLE 5. AJCC TNM classification 
 
Stage Tumor (T) Node (N) Metastasis (M) Grade (G) Description 
I T1a, T1b, T2a, T2b N0 M0 G1-2 Low grade 
II T1a, T1b, T2a N0 M0 G3-4 
Small high grade, or large 
superficial high grade 
III T2b N0 M0 G3-4 Large deep high grade 
IV 
Any T 
Any T 
N1 
N0 
M0 
M1 
Any G 
Any G 
Lymph node metastasis 
Distant metastasis 
Modified from Greene et al 2002 
 
5.1.6 Surgical margins 
 
Enneking defined surgical margins according to the width of healthy tissue 
around the resected tumor. He divided margins into radical, wide, marginal or 
intralesional groups. In radical excision, the entire compartment containing an 
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intracompartmental tumor is removed. Wide margin entails intracompartmental 
resection, with a cuff of normal tissue surrounding the tumor. Resection is 
considered marginal when the plane of dissection is within the reactive zone or 
pseudocapsule of the tumor. In intralesional resection there is tumor at the edge 
of the specimen (Enneking et al 1980). Another classification of surgical margins 
is used by the UICC, using the three categories R0-R2, where R0 equals no 
residual disease, R1 microscopic residual disease, and R2 macroscopic 
residual disease (Sobin et al 2002).  
 
McKee et al demonstrated that margins of <1mm and 1-10 mm had significant, 
and equal, negative prognostic value for local recurrence (58% LRFS in both 
groups, compared to 84% for margins >1cm) (McKee et al 2004). A recent 
HUCH analysis of 270 patients with localized STS of the trunk wall or 
extremities showed that to achieve 5-year local-recurrence free survival rates of 
90%, microscopic healthy tissue margin must be at least 2.5 cm (Sampo et al 
2008). Dickinson et al had no local recurrences in patients with margin >20mm, 
but there were only 12 patients in this group. The authors concluded that 1mm 
margins may be safe, but that narrow margins increase the risk of inadvertent 
contamination (Dickinson et al 2006). 
 
It has been convincingly demonstrated that positive surgical margins are a 
negative prognostic factor for all oncological endpoints (Pisters et al 1996 (B), 
Stojadinovic et al 2002, Zagars et al 2003 (A)). The required margin and the 
quality of healthy tissue separating the tumor from the edge of the specimen 
continue, however, to be an issue of debate. A recent review article states that 
the axiom of 2-3 cm margins is not scientifically proven, but is still used in many 
centers despite the increased need for ablative procedures when using a 2-3 cm 
margin instead of 1 cm (Tunn et al 2009). Another unanswered question regards 
the quality of the tissue margin required. According to Enneking’s 
compartmental philosophy an intact fascia is sufficient margin, and a report on 
50 patients with localized, large, high grade lower extremity STS from MDACC 
indicates that also periosteum is a sufficient barrier (Lin et al 2007). 
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5.1.7 Imaging 
 
Radiological imaging is required to appropriately assess and stage STS, and to 
plan surgical and oncological treatment. Goals are to evaluate the location, size, 
homogeneity, and possible calcification of the tumor. Relationship to, or 
infiltration into, nearby vital structures such as nerves or blood vessels is of 
paramount importance for treatment planning.   
 
Radiographs of the suspected STS have historically been the first-line imaging 
method. In addition to being inexpensive and readily available, involvement of 
underlying bone can be assessed. Also, certain typical findings of specific 
diagnoses (such as phleboliths of hemangiomas) can be identified in plain 
radiographs (Knapp et al 2005).  
 
The main imaging modality for extremity STS is MRI. High-quality morphological 
images, multi-plane imaging capability, and lack of ionizing radiation load make 
it the preferred technique for detection, delineation, differential diagnostics, and 
monitoring response to treatment, as well as for postoperative follow-up. It is 
also used for needle-biopsy guidance (Demas et al 1988, Knapp et al 2005, 
Palesty et al 2005, Tzeng et al 2007, Robinson et al 2008). Its accuracy in 
evaluating fascial involvement and relationship of a tumor to adjacent structures 
allows detailed operative planning (Figure 1) (Clarkson et al 2004, Hünerbein et 
al 2007).  
 
For imaging the trunk and intra-abdominal STS, and for evaluation of bone 
involvement, CT is preferred (Fenstermacher et al 2003, Misra et al 2009). CT is 
also the imaging of choice for patients that cannot undergo MRI (Tzeng et al 
2007).  
 
Ultrasonography is readily available and cheap, and can sometimes be of use 
for distinction between solid and cystic masses (synovial cyst, bursa, abscess) 
(Lin et al 2000, Knapp et al 2005). It’s perhaps most important application in 
STS diagnostics is for needle biopsy guidance (Misra et al 2009). Magnetic 
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resonance angiography gives detailed information about vascular supply of 
tumors, and can also be of use in vascular lesions (Knapp et al 2005).  
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) has 
emerged as a new tool in STS imaging (Schuetze et al 2006). FDG allows 
visualization of tissue glucose metabolism activity. Functional imaging by PET 
can be used for STS detection, differential diagnostics, biopsy guidance, for 
distinguishing between recurrences and therapy-related changes, and for 
monitoring of response to treatment (Buck et al 2008, Evilevitch et al 2008, 
Toner et al 2008). PET, especially in combination with CT, has proven useful in 
preoperative TNM-staging (Iagaru et al 2006, Tateishi et al 2009). 18F-
fluorothymidine (FLT) has been studied in assessment of tumor cell 
proliferation, but is still mainly in experimental use (Benz et al 2009) 
 
There has been some discussion on whether plain chest radiographs should be 
performed for all STS patients for staging as most STS metastases are found in 
the lungs. Some recommend a chest CT scan for all patients as the primary 
modality (Misra et al 2009), whereas others advocate selective use of 
FIGURE 1. MRI image of an intramuscular grade 4 MFH of the thigh. 
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modalities, with primary CT recommended for >5cm high grade (AJCC T2) 
lesions only (Robinson et al 2008). A review of 1170 patients found 10% 
metastatic disease at presentation, of which 87% were lung metastases. Plain 
chest radiographs identified 2/3 of these, and the authors conclude by 
recommending chest radiographs for all patients, and primary CT only for 
patients with an abnormality in these. In addition, chest CT is recommended for 
patients with large, deep, or FNCLCC grade 2-3 tumors, and other biologically 
aggressive histological subtypes (including extraskeletal Ewing sarcoma and 
MPNST) (Christie-Large et al 2008).  
 
5.1.8 Natural history and survival 
 
STS frequently present as a painless mass (Figure 2), and has a tendency to 
grow for long periods of time within an anatomical compartment and along 
fascial planes (Robinson et al 2008). The growing mass compresses the 
surrounding tissues, creating a pseudocapsule around the tumor. The tumor 
itself, however, frequently extends into the reactive zone surrounding the 
pseudocapsule, and simple “shellout” procedures result in local failure in up to 
90% of patients (Weiss et al 2001).  
  
FIGURE 2. A primary 4.5 cm extracompartmental grade 4 MFH of the forearm. 
 
 
22 
The most common site for STS metastasis is the lung, with 19-20% of patients 
developing pulmonary metastases (Gadd et al 1993, Billingsley et al 1999). 
Median survival after detection of pulmonary metastases is <12 months (Van 
Glabbeke et al 1999).  
 
Lymph node metastasis is rare, and occurs in 3-4% of STS. Certain histological 
subtypes, namely rhabdomyosarcoma, epitheloid sarcoma, clear cell sarcoma, 
angiosarcoma, and possibly synovial sarcoma, metastasize more readily to 
regional lymph nodes (Fong et al 1993, Riad et al 2004, Andreou et al 2009). 
Even incorporating sentinel node biopsy into the treatment of these extremely 
rare sarcomas has been considered (Andreou et al 2009). 
 
Several well-established prognostic factors for oncological endpoints have been 
identified in large series, and are presented in Table 6. 
 
TABLE 6. Negative prognostic factors for STS survival 
 
Oncological endpoint Negative prognostic factors References 
LRFS Tumor size >10cm, high tumor grade, positive 
surgical margins, extracompartmental tumor 
location, recurrent tumor at presentation, age >50 
(>64), MFH/neurogenic-/epitheloid sarcoma 
Vraa et al1998, 
Stojadinovic et al 2002, 
Eilber et al 2003, Zagars 
et al 2003 (A) 
MFS Tumor size >5cm, high tumor grade, positive 
microscopic margin, leiomyo-/synovial-
/neurogenic-/rhabdomyo-/epitheloid sarcoma, 
(tumor depth?) 
Gustafson 1994 (B), 
Stojadinovic et al 2002, 
Pisters et al 1996 (B), 
Zagars et al 2003 (A) 
DFS Tumor size >5cm, high tumor grade, positive 
surgical margins, recurrent tumor at presentation, 
head/neck or deep trunk localization, age >64, 
rhabdomyo-/epitheloid-/clear cell sarcoma, (tumor 
depth?) 
Zagars et al 2003 (A), 
Kotilingam et al 2006 
DSOS Tumor size >5cm, high tumor grade, positive 
surgical margins, extracompartmental tumor 
location, head/neck or deep trunk localization, 
age >64, rhabdomyo-/epitheloid-/clear cell 
sarcoma 
Vraa et al 1998, 
Stojadinovic et al 2002, 
Zagars et al 2003 (A) 
LRFS = Local recurrence-free survival, MFS = Metastasis-free survival, DFS = disease-free survival, 
DSOS = Disease-specific overall survival. 
 
Among 504 STS patients treated at MDACC developing local or systemic 
recurrence during follow-up, 25% of recurrences were detected in the first 6 
months, and 50% within 1 year and 2 months. 75% of all recurrences had 
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developed by 2 years and 3 months. At 5 years 93% of recurrences had 
developed, but 3% of all recurrences took longer than 10 years to develop 
(Zagars et al 2003 (C)).  
 
In a U.S. report on 3479 patients from the National Cancer Database, including 
all anatomical sites and histological grades, the 5-year DSOS was 55.3%. 
DSOS by stage (AJCC 4th ed) was: stage I = 84.8%, II = 68.9%, III = 62.1%, IV 
= 19.2% (Pollock et al 1996). In 1225 patients with localized STS treated with 
surgery and radiotherapy in at MDACC in 1960-1999, Zagars et al reported the 
following 5-year survival figures: LRFS 83%, MFS 71%, and DSOS 73% 
(Zagars et al 2003 (A)). In a similar material from MSKCC on 1041 patients 
treated in 1982-1994, 5-year LRFS was 83%, MFS 68%, DFS 78%, and DSOS 
76% (Pisters et al 1996 (B)). 
 
In a more challenging subset of patients consisting of 459 high-grade, deep STS 
of the extremities and trunk treated by the Scandinavian Sarcoma Group in 
1986-1993, 5-year LRFS was 77%, MFS 56%, and DFS 46% (Trovik et al 2001 
(A)). 
 
A series from the U.S. reported 5-year LFRS of 88% in 753 localized, 
intermediate- to high-grade extremity STS, with 90% LRFS for 607 primary 
tumors, and 81% for 146 patients presenting with recurrent tumors at 
presentation. Overall 5-year survival was 70%, with no significant difference 
between primary and recurrent tumor groups (Eilber et al 2003). 
 
Lehnhardt et al reported on 140 patients with localized MFH, treated in Bochum, 
Germany in 1996-2004. LRFS was 74%, and OS 72% (Lehnhardt et al 2008), 
which is similar to results on 460 patients with localized MFH from MDACC, with 
LRFS of 78% and OS 73% (Zagars et al 2003 (A)). 
 
In a small series of 62 mainly primary, subcutaneous extremity STS treated in 
Chicago in 1975-1993, LRFS was 95%, DFS 85%, and DSOS 87% (Gibbs et al 
1997).  
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5.2 Surgical treatment of extremity soft tissue sarcoma 
 
As local recurrence occurred in up to 90% of patients after simple excision 
(Weiss et al 2001), amputation became the treatment of choice for extremity 
STS (Cantin et al 1968, Hoekstra et al 2004). In the 1970’s, however, 
introduction of the concept of surgical margins (Simon et al 1976) and the 
combination of surgery with RT helped to improve the results of limb-sparing 
treatment to match those of amputation (Rosenberg et al 1982). Today, limb-
sparing multidisciplinary treatment is the standard treatment for extremity STS 
(Clark et al 2005).  
 
5.2.1 Amputation vs. limb salvage 
 
An amputation rate of 13% in localized extremity STS has been reported from 
MSKCC (Pisters et al 1996 (B)). Trovik et al found 15% amputations in 459 
patients with localized, deep, high-grade lesions. Local recurrence rate was 4% 
in the amputation group compared to 26% after limb-sparing surgery. There was 
no difference in MFS, however (Trovik et al 2001 (A)). Eilber et al reported a 5% 
rate of amputation in 607 primary, localized, intermediate to high-grade 
extremity STS, and 13% for 146 patients with recurrent tumors (Eilber et al 
2003). One study reported a 9.4% amputation rate in a high-volume sarcoma 
center compared to 13.8% in a low-volume center (Gutierrez et al 2007 (B)).   
 
In a study on 408 sarcoma patients with lower extremity disease, 65 of which 
underwent amputation, limb salvage- and below-knee amputee-groups had 
similar oncological outcome. Amputation was, however, associated with 
decreased functional outcome and increased walking aid use, as well as with 
increased anxiety (Pardasaney et al 2006). A recent SSG study on 118 
osteosarcoma patients showed significantly inferior functional outcome in 
amputees compared to patients treated with limb-sparing surgery, as measured 
by both Musculoskeletal Tumor Society (MSTS) score and Toronto Extremity 
Salvage Score (TESS). There was, however, no significant difference in quality 
of life (Aksnes et al 2008). 
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Even in the age of limb-sparing multi-modality treatment, amputation is 
sometimes the only feasible treatment option for extremity STS. Amputation 
should be considered when surgery, including advanced reconstructive 
techniques combined with RT and/or chemotherapy, cannot offer the patient a 
functionally acceptable, painless limb. Amputation should also be considered if 
the patient’s general health or other diseases do not allow for the 
aforementioned therapies to be administered in a safe way. Finally, amputation 
should be offered as a palliative measure for patients with intractable pain, 
uncontrollable local symptoms (bleeding, skin ulceration, risk of infection), or a 
limb rendered useless by neurovascular infiltration (Clark et al 2003 (B), Pisters 
et al 2007(A)). 
 
Amputation and prosthetic fitting is occasionally the fastest and most reliable 
way to achieve oncologic safety as well as acceptable functional results. This 
may be the case especially in lower leg, ankle and foot tumors, as modern 
below-knee prostheses permit a wide range of activities. In other anatomic sites, 
notably in the hand, the situation is quite different, and all effort is made to follow 
limb-sparing protocols (Colterjohn et al 1997, Zahlten-Hinguranage et al 2004, 
Ferguson 2005, Clark et al 2003 (B)) 
 
5.2.2 Reconstructive surgery 
 
Extremity STS surgery frequently results in large soft tissue and bone defects, 
potentially leaving blood vessels, nerves, joints, or bones exposed. In addition, 
wounds need to heal well before postoperative oncologic treatment can be 
administered. For these reasons, and in order to achieve a good functional and 
aesthetic result, reconstructive procedures are frequently employed.  
 
A “graft” is defined as tissue moved to a distant site without a vascular pedicle 
or vascular reconstruction. Conversely, a “flap” either retains its original blood 
supply via a pedicle (local and pedicled flaps), or has blood supply reestablished 
at the recipient site (microsurgical or free flap) (Yenidunya et al 2007).  
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Flaps can be classified according to the intended destination (local, pedicled or 
free flap) their blood supply (direct or indirect), their construction (uni-, 
bipedicled etc.), or their constituents. Flaps may consist of skin, fat, fascia 
(fasciocutaneous flaps), muscle (muscle flaps), or bone (osseous flaps) as well 
as nerve, intestine or omentum. Combinations of these, such as myocutaneous, 
osteocutaneous, osteofasciocutaneous, osteomusculocutaneous are frequently 
used (Hallock 2004, Hallock 2009 (B)).  
 
Traditionally, reconstructive surgeons have used the “reconstructive ladder” 
(Table 7) in choosing the method of reconstruction, always attempting to use the 
simplest and safest method possible (i.e. lower down the “ladder”). Today, 
microvascular reconstruction is a safe procedure, and more sophisticated 
techniques, higher up the ladder, can be used to achieve superior results even 
when simpler methods are available (Mathes et al 1997). 
 
TABLE 7. The “Reconstructive ladder” 
 
Complexity Reconstructive method 
More complex Free flap 
 Pedicled flap 
 Local flap 
 Skin graft 
Less complex Direct closure 
Modified from Willcox et al 2000 
 
In 257 extremity STS patients treated at our institution, direct closure was 
possible in 41% of patients. Skin grafting only was used in 15%, local skin flaps 
in 5%, pedicled flaps in 12%, and microvascular flaps in 14% of patients (Popov 
2005). Clarkson et al reported using pedicled flaps in approximately 20% and 
microvascular flaps in 5-10% of extremity STS patients (Clarkson et al 2004). In 
42 patients with mostly trunk and lower extremity STS (including 14 DFSP), 
Papadopoulos et al reported direct closure in only 5%, whereas 83% of patients 
received pedicled and 12% free flaps (Papadopoulos et al 2006). A recent study 
found that sarcoma size >2.5 cm was associated with increased need for flap 
coverage in the hand (Talbot et al 2008).  
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Myocutaneous flaps provide well-vascularized tissue that withstands both RT 
and chemotherapy well, facilitating wound healing after tumor resection (Kane et 
al 1999, Spierer et al 2003, Temple et al 2007). There were less complications, 
fewer secondary procedures, greater limb salvage rate, and shorter 
hospitalization times among 41 patients that underwent flap reconstruction (36 
free and 5 pedicled) as compared to a 37-patient direct closure group, when all 
patients had received preoperative RT (Barwick et al 1992). In a series of 173 
extremity STS patients preoperatively treated with RT, major wound 
complications were as frequent in both direct closure and reconstructive surgery 
groups, although patients who were treated by the reconstructive surgery 
service were preoperatively considered high-risk patients for wound 
complications (Tseng et al 2006).  
 
5.2.3 History of microsurgery  
 
Pioneering work on vascular anastomoses was performed by Alexis Carrel who 
was awarded the Nobel Prize in 1912 for his work on vascular sutures and 
transplantation. He also experimented with extremity replantation in dogs as 
early as 1906 (Kocher 1995). The first to reportedly use an operating 
microscope was Swedish otolaryngologist Nylén. The binocular microscope was 
first used by Holmgren in 1923 (Armstrong et al 2001, Tamai 2009). In 1960 
Jacobson and Suarez used the microscope to achieve successful anastomoses 
in small vessels of less than 1 mm diameter, pioneering microvascular surgical 
practice (Jacobson et al 1960). 
 
In 1962 Malt performed the first successful macroreplantation of an extremity, 
reattaching the arm after traumatic above-elbow amputation (Malt et al 1964). 
The following year Kleinert and Kasdan managed the first successful 
microvascular revascularization of an ischemic thumb (Kleinert et al 1963). 
Komatsu and Tamai performed the first successful replantation of a completely 
amputated digit in 1965 (Komatsu et al 1968). 
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Cobbett reported the first toe-to-hand transfer in western literature in 1969 
(Cobbett 1969), although toe-to-thumb transfers were done in China as early as 
1966 (Buncke 1995, Tamai 2009). McLean and Buncke performed the first 
omental free flap in 1972 for a scalp defect (McLean et al 1972), and Harii 
performed the first cutaneous free flap in 1972 for hair transplantation (Harii et al 
1974). Daniel and Taylor used the hypogastric flap for lower extremity 
reconstruction in 1973 (Daniel et al 1973). The 1970’s saw the introduction of 
several new cutaneous and muscle or myocutaneous flaps, many of which are 
still among the most used free flaps. Ueba and Fujikawa pioneered free 
vascularized bone transfer in 1973 (Ueba et al 1983), although Taylor published 
the first reports in 1975-1976 (Taylor et al 1975, Taylor et al 1976). A more 
recent addition has been the introduction of perforator flaps by Koshima and 
Soeda in 1989 (Koshima 1989).  
 
Transplantation of tissues between two individuals (allotransplantation) has its 
origin in the first organ transplant, a kidney transplant between identical twins 
performed by Murray in 1954 (Harrison et al 1956). Only three years later 
Peacock performed the first composite tissue allotransplant with an en bloc 
flexor tendon mechanism transplantation (Peacock 1960). More recent 
developments in the field of composite tissue allotransplantation were the first 
hand allotransplant in 1998 (Dubernard et al 1999), and the first facial 
allotransplant in 2005 (Devauchelle et al 2006). 
 
5.2.4 Microsurgical reconstruction in extremity soft tissue sarcoma 
 
The goals of reconstruction after STS surgery are wound coverage and tension-
free closure, obliteration of dead space, restoration of form and of function when 
possible, as well as achieving a satisfactory aesthetic result. (Langstein et al 
1999, Pederson 2001, Saint-Cyr et al 2006). The first report on using 
microvascular surgery to reconstruct defects after sarcoma surgery was from 
Japan in 1986, where two STS and four osteosarcoma patients were treated 
with free flap reconstruction (5 vascularized fibula and 1 gracilis muscle flap). 
One fibula flap was lost, but the authors concluded that the technique seemed 
 
 
29 
promising (Usui et al in 1986). Today, microvascular reconstruction is used for 
12-18% of patients after resection of extremity STS (Lohman et al 2002, Kim et 
al 2004 (A), Popov et al 2005, Papadopoulos et al 2006). Free flap success 
rates after extremity STS surgery are 94-100%, equal to success rates in other 
indications (Barwick et al 1992, Hidalgo et al 1998, Johnson et al 2002, Kim et 
al 2004 (A), Basheer et al 2008). 
 
5.2.4.1 Pedicled vs. free flaps 
 
It has been stated that the only advantages of pedicled flaps over free flaps are 
shorter operative time, and lesser amount of expertise required (Kane et al 
1999, Hoy 2006). Local and pedicled flaps disrupt local blood and lymphatic flow 
(Serletti et al 1998); some pedicled flaps also disrupt additional muscles in the 
affected limb, leading to further impairment of function. The use of adjacent and 
thus radiated tissue for coverage is discouraged in the setting of preoperative 
RT (Hoy et al 2006). Free flaps have been considered better suited particularly 
for large defects frequently cased by excisions of large, deep seated STS, in 
which RT and chemotherapy are required (Kane et al 1999).  
 
Free flaps offer several advantages in extremity reconstruction after sarcoma 
resection (Figure 3). Large amounts of tissue with independent blood supply can 
be used without the limitations of rotational arcs. Composite flaps containing 
skin, fascia, muscle, bone, and even tendons, blood vessels, and nerves can be 
customized (Chang et al 2000, Carlson 2006). Flap safety is increased by using 
tissue from outside irradiated fields (Carlson 2006), and the well-vascularized 
tissue of free flaps is highly tolerant to wound complications, as well as to RT 
and chemotherapy (Peat et al 1994, Evans et al 1997, Kim et al 2004 (A), 
Ferguson 2005, Tseng et al 2006). High vascularity may even enhance delivery 
of chemotherapeutic agents to the resection site (Chang et al 2000). In a large 
series on 400 free flaps for oncological defects Disa et al reported 97% flap 
success rate, with all surviving flaps healing uneventfully, resulting in no delay in 
administration of RT or chemotherapy (Disa et al 1997).  
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5.2.4.2 Choice of flap 
 
A variety of flaps are available for each anatomic region, and to some extent, 
the method of reconstruction is dependent on the experience and preference of 
the surgeon. Some flaps have, however, been more frequently used than others 
in extremity reconstruction. Factors influencing free flap choice after tumor 
resection include recipient site-dependent factors such as defect location, size, 
and depth, types of tissue requiring reconstruction, need for functional 
reconstruction, and cosmetic considerations. In addition to these, flap reliability 
and also donor site-dependent factors such as the effect of previous surgery or 
RT, and donor site morbidity need to be considered.  
 
Upper extremity 
 
The shoulder region and upper arm can generally be reconstructed with a 
pedicled LD or thoracodorsal artery perforator (TAP) flap if previous treatment 
has not compromised the vascular pedicle. The LD can also be used in the arm 
as a (pedicled or free) functional flap when including motor innervation (Chang 
et al 2000).  
 
FIGURE 3. Grade 3 subcutaneous MFH of the knee treated with a musculocutaneous ALT flap. 
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For the elbow region, a pedicled radial forearm flap has been recommended. 
The functional free gracilis muscle is well suited for functional repair of finger 
and wrist flexion or extension (Langstein et al 1999, Chang et al 2000). Fascial 
or fasciocutaneous flaps such as the radial forearm, lateral arm, scapular, ALT 
or temporoparietal fascia flaps are thinner and may be superior to muscle flaps 
covered with skin grafts depending on the recipient site. Fascial flaps also make 
good gliding surfaces for tendons. (Willcox et al 2000, Pederson 2001, Saint-Cyr 
et al 2006).  
 
When local solutions are not available for the forearm and hand, small free flaps 
such as gracilis, or serratus muscles are preferred (Langstein et al 1999, Chang 
et al 2000, Pederson 2001). Free toe transfer is a useful method for finger 
reconstruction (Pederson 2001). 
 
Lower extremity 
 
In the proximal lower limb pedicled rectus abdominis flaps can be used for 
reconstruction of a range of proximal thigh defects, whereas free flaps are 
required for reconstruction of large defects of the distal thigh. As large volumes 
are frequently needed, a free LD flap is useful (Langstein et al 1999).  
 
Defects around the knee can generally be covered with pedicled gastrocnemius 
flaps, and pedicled soleus flaps can cover most middle lower leg defects 
(Langstein et al 1999, Chang et al 2000).  
 
In the distal third of the leg local soft tissues are sparse and free flaps are 
frequently needed. For deep defects, reliable muscle or musculocutaneous flaps 
are preferred, although perforator flaps offer minimal donor morbidity and less 
bulk, achieving more precise restoration of form (Langstein et al 1999, Chang et 
al 2000).  
 
For reasonably small defects of the distal lower leg, ankle and proximal foot, the 
fasciocutaneous sural flap can be used. (Levin 2008). Also thin ALT flaps can 
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be utilized, and in sole of foot reconstruction the ALT with the lateral femoral 
cutaneous nerve can be used as a sensorineural flap (Ferguson 2005). Flap 
sensibility in sole of foot reconstruction has, however, not been proven to 
prevent wound breakdown (Rautio 1991).  
 
For long bone defects of the extremities the vascularized fibula flap, which can 
also be harvested as an osteocutaneous or osteomusculocutaneous flap, is 
preferred. A double-barrel configuration can be used in weight-bearing bones for 
additional stability (Pederson 2001, Saint-Cyr et al 2006).  
 
After amputation, fillet flaps are useful for stump reconstruction and can cover 
defects of up to 50x70cm without any donor site morbidity (Langstein et al 1999, 
Chang et al 2000, Saint-Cyr et al 2006). In the case of finger amputation fillet 
flaps are useful for hand reconstruction and salvage (Talbot 2008). 
 
5.2.4.3 Functional outcome after free flap reconstruction  
 
Several authors have reported good functional outcome after extremity 
microvascular reconstruction. In a recent report from Japan on 19 sarcoma 
patients with microvascular reconstructions of the hand and forearm, mean 
MSTS score was 25.0 (Muramatsu et al 2009). Serletti et al found a mean 
MSTS score of 28.2 of 30 after free flap reconstruction in 16 patients with 
extremity sarcoma treated with limb salvage and RT. Lowest scores were for 
range of motion, whereas emotional acceptance scores were high (Serletti et al 
1998). Contrary to these findings, Kim et al found low scores for emotional 
acceptance and also for manual dexterity in upper extremity microvascular 
reconstruction patients. In addition, lower average scores as compared to 
patients treated with non-microvascular reconstruction (MSTS score 20.1 vs. 
24.1) were reported. The authors noted that the average scores seemed to 
improve with time, and more so in the microvascular group, the results being 
comparable between the two groups at 5 years (Kim et al 2004 (B)). A report on 
54 patients treated with muscle flaps for extremity sarcomas found an average 
MSTS score of 27.1, but results of free flap and pedicled flap groups were not 
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compared (Hoy et al 2006). Similar results were reported in 55 sarcoma patients 
after flap reconstruction, with average MSTS score of 26.5 for upper and 21.4 
for lower extremity patients (Morii et al 2009).  
 
Rivas reported better function in 16 patients receiving free flaps than in 9 
patients with pedicled flaps in the lower extremity after tumor resection (Rivas et 
al 2006), whereas Serletti found no difference in function between 17 pedicled 
and 16 free flap patients after extremity sarcoma resection (Serletti et al 1998).  
 
Doi et al reported on 17 patients with extremity STS treated with free functional 
muscle flaps. Successful reinnervation was achieved in 16 flaps, and good 
functional results were achieved. The authors conclude by recommending 
functional reconstruction for young patients when tumor resection will result in 
severe loss of motor function (Doi et al 1999). 
 
5.2.5 Forequarter amputation 
 
Extremity amputation for curative treatment of malignant disease is performed 
when functionally acceptable results cannot be achieved with limb-sparing 
treatment. The other indication for amputation is palliation, i.e. relieving 
symptoms to improve quality of life even when there is no curative treatment 
option available.  
 
Forequarter amputation includes the removal of the upper extremity with the 
scapula and part of the clavicle (Berger 1887). It is one of the most mutilating 
procedures in surgical oncology, but useful for curative and palliative treatment 
of proximal arm and shoulder girdle tumors (Keevil 1949, Malawer et al 2001). 
Several authors have modified the operative technique and approach, and the 
amputation can now be extended to include large chest wall resections when 
required (Littlewood 1922, Stafford et al 1958, Pressman 1974, Tukiainen et al 
2003, Ferrario et al 2004).  
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Due to removal of the entire prominence of the shoulder, there is normally 
sufficient skin to close the wound primarily with a local fasciocutaneous flap as 
described in the original technique (Berger 1887). When larger skin defects are 
caused, reconstructive surgery is needed. Muscle transpositions have been 
used, but pedicles of local flaps are frequently located within fields of earlier 
surgery or RT and are thus of questionable reliability. For microvascular 
reconstruction, LD, RA and TFL flaps have been used (Cordeiro et al 2001). 
These can be combined with rib grafts, methylacrylate or mesh for chest wall 
stability (Arnold et al 1984). An alternative with the advantage of eliminating 
donor site morbidity is using a fillet flap from the amputated extremity (Figure 4), 
incorporating the underarm bones for chest wall reconstruction when required 
(Schmidt et al 1987, Kuhn et al 1994). 
 
5.2.6 Pulmonary metastasectomy 
 
In 94 patients with a minimum follow-up of 5-years treated with pulmonary 
metastasectomy at the Roswell Park Cancer Institute in 1976-2000, actuarial 5-
FIGURE 4. Preparation of the free forearm fillet flap after forequarter amputation.  
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year DFS was 5%, and OS 15% (Smith et al 2008). A recent review on 
pulmonary metastasectomy for STS reported 5-year overall survival rates of 25-
38% for a select subgroup of patients with resectable metastases and a 
controlled primary tumor (Pfannschmidt et al 2009). 
 
5.2.7 Prosthetic considerations 
 
Functional results after tumor resection and limb sparing surgery are generally 
good to excellent (Serletti et al 1998, Kim et al 2004 (B), Rivas et al 2006, 
Wright et al 2008), also after free flap reconstruction (Morii et al 2009, 
Muramatsu 2009).  
 
Modern lower limb and especially below-knee prostheses are very functional 
and permit several normal activities. Due to numerous ranges of motion 
required and the importance of manual dexterity, upper limb prosthesis 
functionality is poor as generally only one joint can be moved at a time (Kuiken 
et al 2007). Artificial limb use after forequarter amputation has been unpopular 
due to lacking functionality (Bhagia et al 1997, Clark et al 2003 (A)).  
 
Technological advances in myoelectric prostheses, together with targeted 
reinnervation surgery and the development of new, improved neural machine 
interfaces have shown promising results. These allow intuitive control of multi-
degree of freedom-prosthetic devices, and in one case even sensory feedback 
after targeted reinnervation surgery (Ohnishi et al 2007, Kuiken et al 2007, 
Kuiken et al 2009).  
 
5.3 Oncologic treatment of extremity soft tissue sarcoma 
 
The basis for modern treatment of extremity STS was laid with the realization 
that a combination of limb-sparing surgery and radiotherapy achieved local 
control rates equal to those seen after amputation (Rosenberger et al 1982). At 
present the routine use of adjuvant chemotherapy remains controversial and a 
subject of debate. Surgery remains the mainstay of, and the only curative 
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treatment for STS, but the majority of patients receive oncologic treatment, 
mainly radiotherapy, in addition. 
 
5.3.1 Radiotherapy 
 
Radiotherapy is combined with surgery to improve oncologic outcome, but has 
the potential to cause complications negatively affecting functional outcome. RT 
can be delivered either as external beam radiotherapy (EBRT), or less 
frequently as brachytherapy, which involves placing catheters containing 
radioactive material into the wound during surgery. Also the combination of both 
has been used (Alektiar et al 2005, Clark et al 2005).  
 
Adjuvant RT improves local control rates in extremity STS, and the effect is 
more marked in deep-seated, high grade lesions (Yang et al 1998, Jebsen 
2008). In 164 patients receiving postoperative brachytherapy, improved local 
control was seen only in high grade tumors (Pisters et al 1996 (A)). In 
prospective, randomized trials no improvement in disease-free or overall 
survival attributable to RT has been seen. Not all patients require adjuvant RT, 
however. A recent prospective study concluded that carefully selected patients 
with <5cm tumors could be safely treated with R0 resection only, requiring no 
further treatment (Pisters et al 2007 (B)), supporting earlier findings from 
retrospective studies (Rydholm 1991, Khanfir et al 2003). 
 
Adjuvant EBRT can be given either pre- or postoperatively, and the sequencing 
of surgery and radiotherapy has been an issue of much debate. No difference in 
local control or survival has been shown between the two options, but smaller 
doses of radiation and smaller fields can be used when RT is given 
preoperatively (50 Gy) compared to postoperative administration (60-66 Gy) 
(Nielsen et al 1991, Clark et al 2005). This has been expected to increase 
radiation-related complications in postoperatively treated patients, as doses > 
60 Gy have been shown to increase fibrosis and impair functional outcome 
(Robinson et al 1991). On the other hand, preoperative treatment may interfere 
with final histopathological examination (Suit et al 1985). 
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Retrospective reviews showed that preoperatively treated patients had more 
acute wound complications (Cheng et al 1996), but that postoperative treatment 
resulted in more late radiation-associated complications (Zagars et al 2003 (B)). 
In 2002, the results of a randomized, controlled, multi-center trial from Canada 
were published. This study and its follow-up showed 35% major wound 
complications after preoperative RT compared to 17% in the postoperatively 
treated patients. Wound complications were significantly more frequent in the 
lower extremity. No definitive difference in functional outcome was found, but 
the postoperatively treated patients had significantly more late fibrosis, and also 
more joint stiffness and edema, although the last two were not statistically 
significant findings. The authors conclude that the risk of immediate wound 
complications must be assessed for each patient depending on tumor location 
and weighed against the increased risk of late radiotherapy-associated 
complications and decreased functional outcome (O’Sullivan et al 2002, Davis 
et al 2005). Modern techniques of RT delivery with tighter dose control help 
reduce radiation-associated morbidity to the surrounding tissues, without 
compromising local control (Alektiar et al 2008). 
 
Radiotherapy can also be used in the palliative setting for painful bone 
metastases or for tumors causing bleeding, compression symptoms or skin 
ulceration when operative treatment is not possible. Palliative radiotherapy is 
effective for decreasing spinal or mediastinal compression caused by metastatic 
disease (Kwok et al 2008) 
 
5.3.2 Chemotherapy 
 
It is generally agreed that resectable low-grade and small high-grade STS 
(AJCC Stage I-II) do not need routine chemotherapy (Pisters et al 2007 (B)). An 
effective chemotherapy regimen is, however, desperately needed to improve the 
outcome of patients with high risk tumors (AJCC Stage III), as survival rates in 
this group are poor. The favorable effect of chemotherapy on survival is 
confirmed in Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma. The 
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majority of pediatric sarcoma patients undergo chemotherapy (Robinson et al 
2008, Tunn et al 2009).  
 
Adjuvant chemotherapy for STS is controversial. It has generally been based on 
doxorubicin alone or more recently in combination with ifosfamide, or in 
combination with mesna, ifosfamide and dacarbazine (MAID protocol). A meta-
analysis by the Sarcoma Meta-Analysis Collaboration from 1997, including 14 
randomized controlled trials, found improved rates of LRFS, MFS, and DFS, but 
no statistically significant improvement in OS in patients with localized, 
resectable STS (Sarcoma Meta-Analysis Collaboration 1997). In an updated 
meta-analysis, including the previous 14 and 4 new studies, a small but 
statistically significant improvement in all endpoints could be seen. A 3-5% 
absolute risk reduction was seen for local recurrence, 9-10% for distant 
recurrence and 9-12% for overall recurrence in patients receiving adjuvant 
chemotherapy. An absolute risk reduction of 6% (95% CI 2-11%, p = 0.003), 
from 46% to 40% risk of death was shown in all studies combined. In addition, in 
five studies where doxorubicin was combined with ifosfamide, the absolute risk 
reduction was 11% (95% CI 3-19%, p = 0.01), with risk of death reduced from 
41 to 30%. The authors conclude, however, that the statistically significant 
findings are not necessarily clinically significant, and that use of adjuvant 
chemotherapy should be based on individual evaluation of each patient and the 
risks of chemotherapy (Pervaiz et al 2008). As noted by Pisters et al, it should 
be kept in mind that while the survival benefit of chemotherapy may be 
controversial in studies containing all STS subtypes, the effect may be more 
marked in chemosensitive histological types such as synovial and round cell 
sarcoma (Pisters et al 2007 (A)). Given the rarity of STS, and the even greater 
rarity of individual subtypes, it will be very difficult to produce reliable evidence 
of such an effect.  
 
In addition to the possible benefits of chemotherapy on survival, chemotherapy 
has been used preoperatively for downstaging tumors prior to surgery (Pisters 
2007(C)). One study found that downstaging led to a decrease in the planned 
extent of surgery in 13% of patients. Regrettably, tumor progression during 
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preoperative RT treatment led to an increase in the extent of surgery in 9% of 
patients (Meric et al 2002). 
 
A recent randomized study showed improved rates of local recurrence-free and 
disease-free survival after treatment with neo-adjuvant chemotherapy and local 
hyperthermia compared to chemotherapy alone (Issels et al 2010) 
 
Chemotherapeutic treatment of metastatic STS is palliative in nature (Clark et al 
2005). The most commonly used chemotherapeutic agents are doxorubicin and 
ifosfamide, followed by taxanes and gemcitabine (Pisters et al 2007(A), Maki 
2007, Grimer et al 2010). A new drug of some interest in the palliative 
chemotherapy setting is trabectidin. It has, however, proven to be moderately to 
highly toxic, with mainly hematologic and hepatic adverse effects (Clark et al 
2005, Boudou et al 2009, Le Cesne et al 2009). Seemingly better tolerated is 
the receptor tyrosine kinase inhibitor panzopanib, which in a phase II study in 
142 patients showed freedom from progression at 12 weeks in 39-44% of 
patients with non-adipocytic STS (Sleijfer et al 2009).  
 
5.3.3 Isolated limb perfusion 
 
Principally used in Europe, isolated limb perfusion (ILP) is an approach for the 
treatment of locally advanced, limb-threatening extremity STS. By isolating it 
from central circulation, the extremity can be perfused with concentrations of 
chemotherapeutic agents that would otherwise be lethal to the patient. Initial 
trials with melphalan had little effect, but when combining melphalan with tumor 
necrosis factor (TNF) alpha and mild local hyperthermia, ILP achieved high 
rates of tumor response, and limb-sparing surgery is possible in 70-100% of 
patients. However, there seems to be no benefit in overall survival rates, and up 
to 10 % of patients suffer from severe locoregional toxic effects (Mocellin et al 
2006, Hohenberger et al 2008, Tunn et al 2009) 
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5.3.4 Molecularly targeted approaches 
 
New molecularly targeted treatment strategies have had a major impact on the 
treatment of gastrointestinal stromal tumor (GIST) with imatinib and similar 
drugs (Blanke et al 2008). Imatinib has also shown effect in the treatment of 
DFSP (McArthur 2007), but while other molecularly targeted therapies are 
currently being investigated in the treatment of STS, so far no clinical 
breakthroughs have been reported (Mocellin et al 2006).  

5.4 Multidisciplinary group approach 
 
Due to the rarity of STS very few physicians are familiar with these tumors and 
their treatment. The cooperation of surgeons, oncologists, pathologists and 
radiologists is required for optimal treatment. This has prompted the formation of 
specialized multidisciplinary groups (Rydholm 1997).  
 
The beneficent effect of multidisciplinary care was demonstrated first in 
Scandinavia. Gustafson et al showed that the risk of local recurrence was 
increased 2.4-fold if patients were not referred to specialist centers, and 1.3-fold 
if referred only after primary surgery elsewhere (Gustafson et al 1994 (A)). 
Results of treatment at HUCH improved drastically after the 1987 formation of a 
soft tissue sarcoma group: 3-year DFS among patients treated in 1960-1975 
was only 36%, whereas the corresponding figure was 69% in patients treated by 
the multidisciplinary group in 1987-1993 (Wiklund et al 1996). In 1851 patients 
treated in Sweden and Norway in 1986-1997, local recurrence rate was 70% in 
patients treated outside sarcoma centers, and only 20% in patients primarily 
treated at sarcoma centers (Bauer et al 2001).  
 
Mankin et al demonstrated that biopsy-related errors and complications such as 
major errors in histological diagnosis, technically poor biopsies, wound 
complications, change in outcome and even unnecessary amputations, were 3-
5 times more likely when the biopsy was performed at the referring institution 
compared to the sarcoma center (Mankin et al 1982). In a follow-up study, 
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results were much the same; errors and complications were 2-12 times more 
likely after biopsies performed at the referral center (Mankin et al 1996).  
 
Clasby et al demonstrated serious shortcomings in the treatment of STS in 
Britain, including lacking histology reports, insufficient surgical margins, ignoring 
necessary further treatment in 67%, and lack of follow-up in 12% of patients. 
The authors concluded that these rare tumors should be treated in specialist 
centers (Clasby et al 1997).  
 
A small series from France showed that only 57% of STS patients had pre-
treatment sarcoma group evaluation, and only 42% had biopsy prior to surgery. 
A 6% rate of local recurrence in patients operated by a dedicated sarcoma 
surgeon, compared to 44% in patients operated by other surgeons was also 
reported (Ray-Coquard et al 2004). When reviewing 104 cases of STS that were 
initially managed outside specialist institution and later referred to Huntsman 
Cancer Institute, the authors found that 37% of histological diagnoses changed 
on review. In addition, 82% of margins deemed wide or excisional at the 
referring institution were in fact margin positive (Randall et al 2004). 
 
Bhangu et al compared the results of 96 patients treated at a specialist centre 
with those of 164 patients treated in 38 district general hospitals in the UK in 
1994-1996 with a minimum follow-up of 5 years. Local recurrence rate was 39% 
for patients treated at a district general hospital, compared to 19% in the 
specialist centre. 5-year OS was 58% in both groups, although the specialist 
centre treated significantly more patients with large, deep, high-grade tumors 
(Bhangu et al 2004).  
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6.  AIMS OF THE STUDY 
 
I To evaluate the suitability of free flap reconstruction after soft tissue 
sarcoma resection near the knee and the feasibility of immediate 
collateral ligament reconstruction.   
II To assess the safety and reliability of free flap use after soft tissue 
sarcoma surgery in the lower extremity, and to evaluate the impact on 
functional outcome.  
III To study the results of microvascular reconstruction of bone and soft 
tissue defects after soft tissue sarcoma resections in the upper extremity 
and implications on upper extremity function.  
IV To examine the results of forequarter amputation for malignancy and the 
microvascular reconstructive procedures used.  
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7.  MATERIALS AND METHODS 
 
HUCH soft tissue sarcoma group protocol 
 
The HUCH soft tissue sarcoma group was founded in 1987 and consists of 
oncologists, plastic surgeons, pathologists and radiologists. In weekly meetings, 
each individual patient is evaluated, and treatment is planned.  
 
Referral status was defined as virgin primary if no procedures or needle biopsy 
only had been performed. Patients were considered to have been referred after 
intralesional operation when either open biopsy or intralesional operation had 
been performed. When a sarcoma had been previously considered widely 
excised and later recurred, referral status was defined as recurrent tumor.  
 
Core- or fine-needle biopsy was used to specify histology and grade. Needle 
biopsies were mainly performed under ultrasonography guidance, CT guidance 
being used in select cases. Clinical examination as well as MRI and CT imaging 
were used for evaluating local and systemic status. For tumor grading, a four-
stage scale was used, with grades 1-2 representing low-grade tumors, and 
grades 3-4 representing high-grade tumors. Tumor size was defined as largest 
diameter of the tumor before sample fixation, as measured by the pathologist.  
 
A tumor was considered to be subcutaneous if situated entirely in the 
subcutaneous space without infiltrating the underlying muscle fascia. A tumor 
completely located within a muscle was considered to be intramuscular. Both 
subcutaneous and intramuscular tumors, as well as ones situated inside a 
muscle compartment without compromising the intercompartmental fascia were 
defined as intracompartmental. Any tumor infiltrating a fascial plane between the 
subcutaneous tissue and an underlying muscle, or penetrating an 
intercompartmental fascia was defined as extracompartmental. All bone-
infiltrating tumors were also considered extracompartmental.  
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Surgical margins were defined as wide if the tumor was surrounded by no less 
than 2.5 cm of healthy tissue in microscopical examination, or if an intact fascia 
separated it from the resection margin. Excision was also considered to be wide 
after myectomy of a muscle containing an intramuscular tumor. If the 
microscopic tumor-free margin was less than 2.5 cm, but no tumor cells were 
found at the edge of the specimen, resection was considered marginal. If, 
however, malignant cells were present at the edge of the specimen, margins 
were considered intralesional.  
 
When wide surgical margins were achieved, no further treatment was 
considered necessary. Marginal surgery was followed by postoperative RT at a 
dose of 50 Gy during 5-6 weeks, with an optional 10 Gy boost. Intralesional 
margins were not accepted, and re-operation aimed at wider margins. If 
necessary, amputation was performed. 
 
Treatment was considered adequate after wide resection, or after marginal 
surgery combined with postoperative RT. Marginal surgery alone, or 
intralesional margins not leading to re-operation were considered inadequate. 
 
Selected patients with large tumors received preoperative RT to improve 
resectability. In the early years of the sarcoma group, neoadjuvant or adjuvant 
chemotherapy was administered only to patients with extraskeletal Ewing’s 
sarcoma and related tumors. Later, adjuvant chemotherapy indications were 
modified to include age less than 70 years, high tumor grade, and two of the 
three following factors: tumor size > 8.0 cm (5.0 cm for synovial sarcoma), 
tumor necrosis, or vascular invasion in histopathological examination 
 
Follow-up length for STS was five years if no disease recurrence occurred. 
High-grade lesions were followed at two-month intervals during the first year, 
and every six months after that. For patients with low-grade tumors, follow-up 
interval was 4-6 months throughout follow-up. In addition to clinical examination, 
ordinary chest X-ray was performed during each visit. CT or MRI of the 
operative area was performed annually, beginning at six months after operation. 
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Patients and methods (Studies I-IV) 
 
The study population consisted of a total of 116 patients that underwent 118 
operations at Helsinki University Central Hospital (HUCH) or Oulu University 
Hospital (OUH). There were 95 patients treated for STS with curative intent, and 
these were included in final survival analysis. Median age was 55 years (range 
13-85), with 58 males (50%), and 58 females (50%). Tumor characteristics are 
given in Table 8.  
 
Patient records of HUCH and OUH were retrospectively reviewed for data on 
patient demographics, treatment details and outcome. When necessary, data on 
long term-follow up and functional result was acquired from other hospitals. 
 
Patients and methods (Study I) 
 
15 patients treated by the HUCH soft tissue sarcoma group in 1993 – 2005 for 
STS at near the knee joint requiring free flap reconstruction after tumor excision 
were included. There were 6 male and 9 female patients. Median patient age 
was 66 years. Eight patients were referred for virgin primary tumors, 2 for 
primary tumors after intralesional operation, and 4 for recurrent tumors.  
 
Patients and methods (Study II) 
 
73 lower extremity tumor patients were treated with free flap reconstruction were 
included. 15 patients had a resection of STS in the knee area, and had been 
previously included in study I. 72 patients were treated for STS, and one for 
recurrent malignant villonodulary synovitis. All patients were treated with 
curative intent. There were 31 male and 42 female patients, and median age 
was 53 years. 32 patients were referred for virgin primary tumors, 22 for primary 
tumors after intralesional operation, 14 for recurrent tumors and 5 for 
complications after recent STS surgery.  
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TABLE 8. Tumor characteristics of 116 patients 
 
 
II* 
(n=73) 
Study  
III 
(n=20) 
 
IV** 
(n=23) 
 
Total 
(n=116) 
% 
 
Tumor size (cm)      
Median 6.0 5.0 10.0 6.0  
Range 1.2 - 35.0 1.8 - 29.0 5.2 - 29.0 1.2 - 35.0  
Tumor location      
Foot 10   10 8.6 
Ankle 3   3 2.6 
Lower leg 20   20 17.2 
Knee 18   18 15.5 
Thigh 9   9 7.8 
Hip region 13   13 11.2 
Hand  1  1 0.9 
Wrist  2  2 1.7 
Forearm  13  13 11.2 
Elbow  1  1 0.9 
Upper arm  2 1 3 2.6 
Shoulder  1 22 23 19.8 
Histopathologic diagnosis      
MFH 37 8 8 53 45.7 
Synovial sarcoma 9 2 1 12 10.3 
Leiomyosarcoma 7   7 6.0 
Fibrosarcoma 2 2 2 6 5.2 
Sarcoma NOS 3 2 1 6 5.2 
MPNST 1 1 2 4 3.4 
Myxoid liposarcoma 4   4 3.4 
Ductal carcinoma (of breast)   3 3 2.6 
Angiosarcoma   2 2 1.7 
Chondroblastic osteosarcoma   2 2 1.7 
Epitheloid sarcoma 1 1  2 1.7 
Adenocystic carcinoma   1 1 0.9 
Borderline mesenchymal tumor 1   1 0.9 
Chondrosarcoma 1   1 0.9 
Dedifferentiated chondrosarcoma 1   1 0.9 
Desmoid tumor  1  1 0.9 
DFSP  1  1 0.9 
Extraskeletal chondrosarcoma  1  1 0.9 
Extraskeletal osteosarcoma 1   1 0.9 
Liposarcoma 1   1 0.9 
Malignant hemangiopericytoma 1   1 0.9 
Malignant villonodulary synovitis 1   1 0.9 
Myxoid MFH  1  1 0.9 
Myxofibrosarcoma 1   1 0.9 
Pleomorphic liposarcoma 1   1 0.9 
Spinocellular carcinoma   1 1 0.9 
Tumor malignancy grade***      
High 56 16 18 90 77.6 
Low 16 2  18 15.5 
Tumor compartment      
Extracompartmental 45 17 23 85 73.3 
Subcutaneous 24 3  27 23.3 
Other intracompartmental 4   4 3.4 
SUM 73 20 23 116  
* All 15 patients in Study I are included in Study II. ** Two patients included in both Study III and IV are 
reported only with Study III. *** Grade is given for soft tissue sarcomas only. MFH = Malignant fibrous 
histiocytoma, NOS = Not otherwise specified, MPNST = Malignant peripheral nerve sheath tumor, DFSP = 
Dermatofibrosarcoma protuberans. 
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Patients and methods (Study III) 
 
20 patients with upper extremity tumors treated by the HUCH soft tissue 
sarcoma group in 1990 – 2006 with free flap reconstruction were identified. 18 
patients were treated for STS and one each with desmoid tumor and 
dermatofibrosarcoma protuberans (DFSP). Of the 18 STS patients, 16 were 
treated with curative intent. There were 16 male and 4 female patients with a 
median age of 61 years. 7 patients were referred for virgin primary tumors and 6 
for primary tumors after intralesional operation. 7 patients were referred for 
recurrent tumors. 
 
Patients and methods (Study IV)  
 
25 patients treated with FQA in 1989-2008, 20 at HUCH and 5 at OUH, were 
included. Two of these patients had been previously included in Study III. For 
each individual patient, the most suitable method of FQA was utilized, the most 
common being a combined anterior-posterior technique. Microscopical tumor-
free margins were determined only for curatively treated patients, and only if the 
surgeon considered the resection macroscopically wide.  
 
All patients were operated on under general anesthesia with additional epidural 
or brachial plexus anesthesia used frequently later in the series. 
 
Surgical treatment 
 
Patients were treated according to the HUCH soft tissue sarcoma group 
protocol where applicable. Limb-sparing excision of a lower extremity tumor was 
performed in 73 patients, and of an upper extremity tumor in 18 patients.  
 
In all studies combined, 105 free flap operations were performed on 103 
patients. The free latissimus dorsi was the most frequent free flap, used in 59 
cases (56%). Details of free flap procedures are presented in Table 9. 
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TABLE 9. Data on 105 free flap procedures 
 
 
II* (n=75) 
Study        
III (n=20) 
 
IV** (n=10) 
Total 
(n=105) 
 
Operative time (min)      
Mean 355 310 355 350  
Range 180 - 805 195 - 575 305 - 570 180 - 805  
Flap ischemia time (min)      
Median 70 64 79 69  
Range 26 - 268 31 - 216 26 - 162 26 - 268  
Operative blood loss (ml)      
Median 1325 650 4125 1300  
Range 200 - 6300 150 - 8000 2600 - 9400 150 - 9400  
Free flap     % 
Latissimus dorsi 54 5  59 56.2 
Anterolateral thigh 9 1  10 9.5 
Tensor fascia latae 3 3 4 10 9.5 
Forearm fillet  2 6 8 7.6 
Radial forearm 4 4  8 7.6 
Fibula 1 2  3 2.9 
Gracilis 3   3 2.9 
Scapularis  2  2 1.9 
Rectus abdominis 1   1 1.0 
Replantation of forearm  1  1 1.0 
SUM 75 20 10 105  
* All 15 patients in study I are included in study II. ** Two patients included in both Study III and IV are 
reported only with Study III. 
 
In study I, when radical resection of a tumor near the knee joint required 
excision of the collateral ligaments these were sacrificed. When knee instability 
resulted, reconstruction of the collateral ligaments was performed using bone-
patellar tendon-bone graft in six patients (three medial and three lateral 
ligaments), and pes anserinus tendon transposition in one patient (medial 
ligament). External femorotibial fixation was used for 4-6 weeks postoperatively 
before mobilization was allowed. 
 
In study II, wide surgery was attempted when possible. All defects were 
reconstructed with free flaps, and two patients needed two free flaps for 
reconstruction.  
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In study III wide excision of extremity tumors was attempted in 18 out of 20 
patients.  Two patients were treated with primary forequarter amputation. All 
defects were reconstructed using microvascular flaps.  
 
In study IV, wound closure after 
FQA was achieved by using local 
fasciocutaneous flaps when 
permitted by the width of resection. 
Extended FQA with chest wall 
resection was performed in seven 
patients, and reconstruction of 
chest wall stability using free 
forearm fillet flaps, or with free rib 
grafts and synthetic mesh was 
necessary for three of these 
patients. When free flap 
reconstruction was deemed 
necessary, a fillet flap from the 
amputated extremity was preferred. 
When the fillet flap was not 
available, coverage was achieved 
with the ipsilateral TFL (Figure 5). 
When resection resulted in 
instability of the chest wall, 
reconstruction including fillet flap 
bones, rib grafts, or synthetic mesh 
was performed.  
 
Statistical analysis 
 
For statistical analysis, SPSS for Windows (v 13.0, SPSS Inc., Chicago, IL) was 
used in studies I-II, and SPSS for Windows (v 15.0, SPSS Inc., Chicago, IL) in 
studies III-IV. Estimated 5-year survival figures were calculated according to the 
FIGURE 5. Pre- and postoperative view of patient 
treated for recurrent ductal carcinoma of the breast 
with forequarter amputation and reconstruction using a 
microvascular TFL flap. 
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Kaplan-Meier method. Survival differences between groups were analyzed 
using Log-rank test in a univariate model, and significant factors were further 
analyzed in a multivariate model using Cox regression analysis. Factors 
affecting surgical complications were analyzed by chi-square- or Fisher’s exact 
tests. Statistical significance was set at 0.05. 
 
 
 
 
51 
8.  RESULTS 
 
Complications 
 
One patient died during the first postoperative month from a pulmonary 
infection, after curatively intended excision of a 7cm high-grade MFH of the 
knee. Four flaps were lost, giving a free flap success rate of 96%. All flaps lost 
were for reconstruction of lower extremity defects (Study II).  
 
Microvascular anastomosis complications necessitating reanastomosis but not 
resulting in flap loss occurred in 9 of 105 free flap procedures (9%). 
Anastomosis complications occurred in 1 patient (7%) in Study I, 6 patients (8%) 
in Study II, 2 patients (10%) in study III, and 2 patients (17%) in study IV.  
 
Wound complications requiring operative room revision occurred in 18 of 116 
patients (15%). Wound complication rates for studies I-IV were 27%, 26%, 15%, 
and 8%, respectively.  
 
One patient developed severe respiratory failure after extended forequarter 
amputation with resection of ribs I-III, the clavicle, and part of the sternum. This 
was managed with temporary mechanical ventilatory support, and the patient 
recovered without further surgery.  
 
Of the studied factors (patient age, smoking status, diabetes, ASA-group), none 
achieved statistical significance in predicting surgical complications in the 
separate studies. When combining all 116 patients, the only significant predictor 
for wound complications was patient age >55 years. 12% of 60 patients of 55 or 
younger underwent wound revision, compared to 28% of 58 patients over 55 
(p=0.037). A non-significant correlation was seen between smoking and wound 
complication; 17% of non-smokers underwent surgery for wound complications, 
whereas the corresponding number for smokers was 25%.   
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Surgical margins and oncologic treatment 
 
In 95 STS patients treated with curative intent, surgical margins were wide in 43 
patients (45%), marginal in 47 (49%), and intralesional in 5 (5%). Achieved 
margins were comparable in the upper and lower limb. Postoperative RT was 
delivered to 38 of 47 patients (81%) with marginal excision. In 6 patients (13%) 
postoperative RT could not be administered because of previous treatment. 
Three patients (6%) received no RT despite marginal excision. Of five patients 
with intralesional excision, two underwent immediate amputation, and three had 
no further surgery (due to disease spread or patient refusal).  
 
Of 95 curatively treated STS patients, 7 were administered preoperative RT, 
and 57 were administered postoperative RT. Neoadjuvant chemotherapy was 
used in 5 cases, and 14 patients received adjuvant chemotherapy. 
 
Adherence to sarcoma group protocol 
 
Out of 95 curatively treated patients with extremity STS, 89 (94%) were treated 
according to sarcoma group protocol. In three patients with marginal surgical 
margins, RT was omitted after sarcoma group deliberation, based on tumor 
characteristics. In three patients with intralesional margins that did not undergo 
further surgery or amputation, two refused recommended amputation and one 
developed rapidly progressing disease with multiple metastases by the time the 
surgical margin was determined.  
 
Knee stability after sarcoma resection in the knee (Study I) 
 
Collateral ligament excision was done in 9 of 15 patients in Study I. Two lateral 
ligaments were not reconstructed, resulting in lateral knee instability and 
subsequent need for orthosis in one patient. Four medial and three lateral 
ligaments were reconstructed. One patient with medial collateral ligament 
reconstruction suffered recurrent dislocations of the patella, and later underwent 
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correctional surgery. None of six patients undergoing tumor excision without 
collateral ligament resection suffered from knee instability.  
 
Functional outcome after limb-salvage surgery (Studies II and III) 
 
After tumor excision and free flap reconstruction in the lower extremity (Study 
II), 64% of patients could walk normally, 11% had a mild walking impairment not 
necessitating ambulatory aids such as crutches, walking aids or prostheses. 
21% required aids in order to ambulate, and 4% needed a wheelchair.  
 
In 18 upper extremity patients undergoing limb-sparing resection and free flap 
reconstruction (Study III), upper limb function was unaffected in 44% (Figure 6), 
and mildly impaired but not influencing daily life in 11% of patients. 39% of 
patients regained an accessory upper extremity only. One patient underwent 
transhumeral amputation because only intralesional surgical margins were 
achieved despite attempted limb-salvage.  
FIGURE 6. Primary grade 4 extracompartmental sarcoma NOS treated with wide resection. The defect 
was reconstructed with a free musculocutaneous LD. Upper extremity function at 8 months was good. 
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Management of postoperative pain in forequarter amputees (Study IV) 
 
Of 25 forequarter amputees, 11 (44%) developed phantom limb pain after 
amputation. The pain was controlled by pharmacological means or decreased 
with time, and only three patients (12%) experienced significant phantom pain at 
6 months. Two patients died of their disease while still suffering from phantom 
pain, at 2 and 8 months after operation respectively. 
 
Thirteen patients (52%) underwent amputation under general anesthesia, 7 
(28%) also received epidural anesthesia, and 5 (20%) were administered 
additional brachial plexus anesthesia. There was no statistically significant 
correlation between perioperative pain management and development of 
postoperative or long-term phantom limb pain.  
 
Patients using opioids for pre-amputation pain were more likely to develop 
phantom limb pain (70 vs. 27%, p = 0.049).  
 
Oncologic outcome and prognostic factors 
 
Patients treated with palliative intent, and patients with tumors other than soft 
tissue sarcomas were excluded from survival analysis. For the remaining 95 
patients, median follow-up was 61 months (range 0-218). Estimated 5-year 
survival figures for the entire population and the separate studies are presented 
in Table 10.  
 
In Study II, no statistically significant factors predicting local recurrence were 
identified. Adverse prognostic factors for metastasis, disease recurrence, and 
disease-specific overall survival in multivariate analysis were tumor size 
>5.0cm, and extracompartmental location of tumor. In Study III, tumor size 
predicted both local recurrence and death of disease in univariate analysis. 
Tumor grade was an adverse prognostic factor for local recurrence only in 
univariate analysis. In Study IV, palliatively intended treatment was a significant 
adverse prognostic factor for disease specific death.  
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When combining all the 95 curatively treated STS patients, significant 
prognostic factors for LRFS, MFS and DFS were extracompartmental tumor 
location and tumor size >5cm. For DSOS, only extracompartmetal location of 
tumor was significant. High tumor grade was significant in univariate analysis for 
LRFS, DFS and DSOS, but lost significance in multivariate analysis.  
TABLE 10. Outcome of curatively treated soft tissue sarcoma patients 
* All 15 patients in study are included in study II. ** One patient included in study III is also included in 
study IV. LRFS = Local recurrence-free survival, MFS = Metastasis-free survival, DFS = disease-free 
survival, DSOS = Disease-specific overall survival.  
 
 
 
I* (n=15) 
Study 
II (n=72)        III** (n=16) 
 
IV (n=8) 
Total 
(n=95) 
Follow-up (months)      
Median 71 60 74 25 61 
Range 0 - 121 2 - 224 19 - 176 5 - 218 0-224 
LRFS (%) 91.7 81.7 56.5 33.3 73.1 
MFS (%) 59.5 58.8 66.4 37.5 58.3 
DFS (%) 59.5 55.5 45.0 12.5 50.1 
DSOS (%) 76.2 70.4 80.2 31.2 68.9 
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9.  DISCUSSION 
 
Oncological outcome 
 
The treatment of extremity STS has changed fundamentally in the last 40 years 
as primary amputation has been replaced by limb-sparing multimodality 
treatment. Through centralization of care it has become possible for individual 
physicians to evaluate and treat significant numbers of these rare tumors.   
 
Oncological outcome is the foremost concern in the treatment of the surgical 
cancer patient. In the present studies 94% of patients received treatment as 
recommended by the HUCH soft-tissue sarcoma group. 5-year LRFS was 
81.7% in lower extremity STS, but only 56.5% in upper extremity disease. 5-
year DSOS was excellent in both groups, however, 70.4% in the lower and 
80.2% in the upper extremity (Table 10). These are comparable to other studies, 
although direct comparison is difficult due to heterogeneous study populations 
(Table 11).  
 
TABLE 11. Oncological outcome in studies on soft tissue sarcoma 
Author n Extremity 
Percent 
>5cm 
Percent 
high grade 
Percent 
deep 
Percent 
recurrent LRFS 
     5-year 
MFS   DFS DSOS 
Pisters et al 1996 (B) 1041 upper/lower na 60 na na 83 78 68 76 
Gibbs et al 1997 62 upper/lower 32 74 0 0 95 na 81 87 
Vraa et al 1998 316 extr + trunk 50 65 59 18 79 na na 74 
Popov et al 2000 106 lower 41 77 68 19 79 72 63 76 
Trovik et al 2001 (A) 459 extr + trunk 45 (>9cm) 100 50 20 77 56 46 na 
Lohman et al 2002 100 upper 47 70 56 25 87 na na 82 
Eilber et al 2003 146 upper/lower 74 53 na 0 90 na na 70 
Eilber et al 2003 607 upper/lower 74 72 na 100 81 na na 70 
Zagars et al 2003 (A) 1225 extr + trunk 59 71 na 16 83 71 na 73 
Kim et al 2004 (A)* 17 upper 47 94 na 71 50 na na 61 
Popov et al 2004 80 upper 52 84 69 19 79 68 62 75 
Lehnhardt et al 2008 140 upper/lower 78 66 79 66 74 na na 72 
* 16 patients treated with microvascular reconstruction. LRFS = Local recurrence-free survival, MFS = 
Metastasis-free survival, DFS = disease-free survival, DSOS = Disease-specific overall survival, na = data 
not available. 
 
Most upper extremity sarcomas in study III were located distal to the elbow, the 
more proximal ones requiring microvascular reconstruction less frequently, as 
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pedicled flaps can be readily used. The seemingly high rate of local recurrences 
in study III (LRFS 56.5%, Table 10) may reflect the challenging anatomical 
setting; a high density of vital structures may make achieving sufficient surgical 
margins in the forearm and hand difficult. Also, the patient material included 
86% high-grade, and 86% extracompartmental tumors (compared to 78 and 
61% in study II, respectively). Further, the survival analysis of upper extremity 
STS included only 16 curatively treated STS patients, decreasing statistical 
power. Interestingly, the only other study published on upper extremity 
microvascular reconstruction after STS surgery reports very similar outcome 
(LRFS 51%), although 71% of tumors in that series were recurrent (compared to 
only 25% in study III) (Kim et al 2004 (A)).  
 
Suitability of free flap reconstruction in soft tissue sarcoma surgery 
 
Free flap success rate in this series was 96%, a rate comparable to other 
studies on free flap use for reconstruction after oncologic surgery (Barwick et al 
1992, Disa et al 1997, Hidalgo et al 1998, Kim et al 2004 (A)). Microvascular 
reconstruction is thus a safe procedure for STS patients, with low complication 
rates. In order to identify patients at greater risk for flap loss or anastomosis 
complications, larger studies need to be undertaken; in this series no factors 
associated with flap-related complications were identified.  
 
It is conceivable that the importance of free flap reconstruction after oncologic 
surgery may increase in the future as the improvement in survival rates has 
allowed for a shift of focus towards preservation or restoration of function (and 
even of cosmesis when possible). At the same time, as reliability of free flaps 
has increased, reliance on the reconstructive ladder has decreased (Willcox et 
al 2000). Advanced reconstructive methods are sometimes used even when 
simpler ones are available, if a superior functional result can be achieved.  
 
Free flaps have been shown to withstand RT and chemotherapy well, allowing 
for uneventfully healed wounds permitting rapid administration of oncological 
therapy (Peat et al 1994, Disa et al 1997, Evans et al 1997, Kim et al 2004 (A), 
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Ferguson 2005, Carlson 2006, Tseng et al 2006). The results of this series with 
only 15% wound complications support these previous findings, and the great 
majority of patients requiring oncologic treatment were able to begin treatment 
soon after STS surgery.  
 
The latissimus dorsi flap was by far the most frequently used free flap, utilized in 
56% of patients, either as a musculocutaneous or muscle flap. Later in the 
series, the anterolateral thigh perforator flap was used in 10 patients. Perforator 
flaps have become popular in breast reconstruction, and are used frequently for 
reconstructions of both traumatic and oncologic defects in the head and neck as 
well as in the extremities. Reported advantages of perforator flaps are reduced 
donor site morbidity and better aesthetic results when thin flaps are required 
(Geddes et al 2003). Perforator flaps have, however, been criticized for the 
inconsistent and variable anatomy of the pedicle, the inability to produce 
functional flaps and for the long learning curve associated with their use 
(Hallock 2009 (A), Saint-Cyr et al 2009). A major determinant in flap choice after 
soft tissue sarcoma surgery is, however, the ability of the flap to obliterate dead 
space and thereby achieve stable, well-healing wounds. Muscle flaps are often 
better suited for these purposes, as their frequent use in this series shows.  
 
Functional outcome after oncological resection and microvascular 
reconstruction 
 
Most studies on extremity STS report disease-specific survival rates of 70-80% 
at five years, corresponding well to survival in studies I-III. As the majority of 
patients can now be expected to survive for several years after initial operation, 
functional outcome has become a major determinant of the quality of treatment. 
It is no longer enough to remove a tumor in an oncologically safe manner, but 
the surgeon should attempt to achieve optimal functional results. Also, 
functional results should be quantified during follow-up visits, and reported 
together with oncological and surgical results. Functional results in this series 
were generally good, with 75% of lower, and 55% of upper extremity STS 
patients regaining normal or near-normal function during follow up. A weakness 
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of this study is the lack of functional scoring and systematic, quantified 
assessment of functional results. The retrospective nature of the study did not 
allow such information to be collected. An institution concerned with extremity 
reconstruction is expected to be able to quantify functional outcome, and the 
use of one of the several scoring systems (MSTS, TESS etc) would help to 
increase quality and comparability of results.  
 
Numerous reports on reconstruction of injured collateral ligaments have been 
published. Reconstruction after resection for malignant disease on the other 
hand, has been reported in only a few papers. Bickels et al, in a retrospective 
series on 24 patients, reported good stability in 83% of patients after stapling the 
lateral collateral ligament to the lateral tibial metaphysis after proximal fibula 
resection (Bickels et al 2007). Contrary findings were published by Einoder et al, 
who reported satisfactory outcome in six consecutive patients treated with 
proximal fibular resection without ligament reconstruction (Einoder et al 2002). 
No reports on medial collateral ligament reconstruction in oncologic indications 
have been published to date. Considering the width of resection in the reported 
cases, instability would have been anticipated in all seven patients with 
collateral ligament reconstruction. Only one patient did develop instability after 
medial reconstruction, namely lateral patellar instability. The results should 
therefore be seen as convincing, but further studies are nonetheless warranted.  
 
After forequarter amputation upper extremity function is lost altogether. 
Prostheses offer very little functionality, and none of the patients in study IV 
used an upper extremity prosthesis. Other authors report similar results (Bhagia 
et al 1997, Clark et al 2003 (A), Daigeler et al 2009). This is not likely to change 
until better prostheses, offering lighter construction and easier, more versatile 
operation. Some advances have been made, mainly in the field of targeted 
reinnervation, which may offer more intuitive prosthesis control (Kuiken et al 
2007). At present, considering the cost of individual artificial limb fitting, offering 
forequarter amputees a shoulder padding for improving shoulder contour may 
be more recommendable.  
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Forequarter amputation in oncologic surgery 
 
Results of forequarter amputation in this series further establish this procedure 
as a valuable alternative in the treatment of upper extremity and shoulder girdle 
tumors. A DSOS of 44% in the curatively treated group is poor compared to 
results of studies II and III, but compares well to previous results (Rickelt et al 
2009), and must be considered acceptable considering tumor size and difficulty 
of the cases. In our series, all but one patient (4%) would have agreed to the 
procedure when asked afterwards. Palliatively treated patients all experienced 
marked pain relief, indicating that patient selection for palliative FQA is 
successful. In a series on 45 patients treated with proximal extremity 
amputations (62% palliative procedures), a subjective increase in quality of life 
was reported in only 50% of patients, and only 41% of patients would have 
agreed to the procedure in retrospect. The study also showed that high pain 
intensity and poor quality of life preoperatively correlated with improved 
postoperative quality of life (Daigeler et al 2009).  
 
Study IV had no perioperative morbidity, and only 8% wound complications. 
Free flap success rate was 100%, and there were 17% anastomosis 
complications. The low wound complication rate can partly be attributed to the 
cavity filling properties and tension-free closure achieved by liberal use of free 
flaps. Achieving swift and uneventful recovery is all the more important 
considering that the majority of palliative forequarter amputees have limited life 
expectancy, and that the procedure is aimed at improving quality of life.  
 
The results of study IV further show that tumor infiltration into the chest wall is 
no contraindication to FQA, as the amputation can safely be extended to include 
chest wall resection. Attention must be paid, however, to reconstructing a stable 
chest wall allowing effective ventilation (Losken et al 2004). One of the seven 
patients that underwent FQA and chest wall resection developed respiratory 
insufficiency in our series. Ver Halen et al reports one perioperative death due 
to respiratory complications among 16 forequarter amputees (ver Halen et al 
2010), and Rickelt et al also reports one death from respiratory failure in their 
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series on 40 patients that underwent FQA (Rickelt et al 2009). Extended 
amputation routinely requires reconstructive measures in order to achieve 
wound closure. A forearm fillet flap from the amputated extremity should be the 
first choice whenever available. It is a reliable flap with large-caliber vessels for 
anastomosis, and can be elevated with one or both forearm bones included, to 
reconstruct the chest wall or contour of the shoulder (Kuhn et al 1994, Osanai et 
al 2005, ver Halen et al 2010).  
 
Phantom limb pain (PLP) was experienced by 46% of patients in the immediate 
postoperative period. This corresponds well to earlier reports of 41% PLP after 
upper extremity amputation (Flor 2002), and 41% PLP in a series of 16 FQA 
and 7 hemipelvectomy patients (ver Halen et al 2010). Interestingly, PLP was 
significantly more common in patients with opioid-requiring pain preoperatively, 
and all patients receiving treatment for neuropathic pain preoperatively did 
develop PLP. Perioperative epidural pain relief, which has given contradictory 
results in previous studies (Bach et al 1988, Nikolajsen et al 1997), was not 
associated with lower rates of PLP in our series. Routine use of perioperative 
epidural analgesia should perhaps be discontinued until its effect is better 
documented.  
 
Importance of multidisciplinary management 
 
Multidisciplinary team evaluation should be available for all soft tissue sarcoma 
patients. Treatment outside a sarcoma center has been shown to increase risk 
of local recurrence, and by consequence increases morbidity and compromises 
functional outcome (Mankin et al 1982, Mankin et al 1996, Wiklund et al 1996, 
Bauer et al 2001, Bhangu et al 2004). Multidisciplinary evaluation allows for 
optimal planning of diagnostic workup including placement of biopsy tracts so as 
not to complicate upcoming surgery. Timing and sequencing of surgery can be 
planned in advance, and delays in administration of oncological treatment can 
be avoided. In addition, the required plastic surgery expertise should be present, 
as sufficient width of resection frequently cannot be achieved without 
reconstructive surgery. 
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Adherence to sarcoma group protocol in this series was strict, with only 6% of 
patients being treated in discordance with the protocol. All exceptions to the 
protocol were based on either individual assessment of the patient, or on patient 
refusal to undergo treatment. Both surgical and oncological outcome were good 
even in the challenging patient population requiring microvascular 
reconstructions after STS surgery, suggesting that the HUCH sarcoma group 
protocol is well calibrated. The results also indicate that the requirement of a 2.5 
cm healthy tissue margin is sufficient. Adherence to the protocol, however, 
requires readily available reconstructive surgery resources, available in only a 
few centers in Finland. This supports the view that STS should be treated only 
at high-volume centers, where sufficient resources and expertise are available.  
 
The centralization of the treatment of STS patients to large sarcoma centers 
also has the advantage of allowing for centralized follow-up. The median length 
of follow-up in this series was 61 months, one patient even having been 
followed up for 224 months at our institution. Up to 7% of STS recurrences take 
more than 5 years to develop (Zagars et al 2003 (A)), and sufficiently long 
follow-up protocols are necessary in order to recognize recurrences as early as 
possible. Also, long periods of reliable follow-up support research, necessary for 
the continued development of treatment of this challenging group of tumors.   
 
The rarity of soft tissue sarcomas and even greater rarity of individual subtypes 
makes it difficult for all but the largest sarcoma centers to produce sufficiently 
large numbers of patients for significant prospective studies to be carried out. 
The continued quality of sarcoma research depends on close national and 
international cooperation between sarcoma centers. 
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10.  CONCLUSIONS 
  
I Microvascular reconstruction is a safe and reliable method of 
reconstructing defects after soft tissue sarcoma surgery near the knee. 
Reconstruction of collateral ligaments can be performed concurrently with 
tumor resection, and may increase postoperative knee stability.  
II Lower extremity microvascular reconstruction after soft tissue sarcoma 
resection is safe and reliable. Oncological outcome is excellent. Wound 
complications are infrequent, and functional results are good.  
III Free flap surgery after upper extremity soft tissue sarcoma surgery is an 
effective and safe method of reconstructing bone and soft tissue defects. 
Low wound complication rates are achieved, and functional results are 
satisfactory. 
IV Forequarter amputation remains a useful treatment option for malignant 
tumors of the proximal upper extremity and shoulder girdle. FQA is safe 
even when extended to include chest wall resection. Curative treatment 
is possible in selected patients, and considerable intervals of improved 
quality of life can be achieved for palliatively treated patients. After 
forequarter amputation, the preferred free flap is a fillet flap from the 
amputated extremity. It is reliable and versatile, and eliminates the 
problem of donor site morbidity. The fillet flap provides a solution for soft 
tissue coverage as well as reconstruction of chest wall stability. 
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